PMV Pharmaceuticals, Inc.
PMVP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001699382
No open-market purchases or sales by PMV Pharmaceuticals, Inc. insiders were filed in the last 90 days; 64 institutions reported holding it in 13F filings for Q2 2026, worth $45.9M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in PMV Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +15 vs. Q3 2021
- Shares held
- 47.5M
- +3.51M (+8.0%) vs. Q3 2021
- Total value
- $1.10B
- −$213.4M (−16.3%) vs. Q3 2021
- New holders
- 24
- 42 more added
- Sold out
- 9
- 22 more reduced
2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PMVP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 64 | $45.9M |
| Q1 2026 | 69 | $45.8M |
| Q4 2025 | 63 | $46.8M |
| Q3 2025 | 64 | $52.5M |
| Q2 2025 | 54 | $36.8M |
| Q1 2025 | 55 | $40.7M |
| Q4 2024 | 70 | $58.8M |
| Q3 2024 | 74 | $58.2M |
| Q2 2024 | 93 | $65.6M |
| Q1 2024 | 99 | $72.7M |
| Q4 2023 | 98 | $144.0M |
| Q3 2023 | 104 | $333.0M |
| Q2 2023 | 106 | $324.0M |
| Q1 2023 | 113 | $245.7M |
| Q4 2022 | 115 | $474.5M |
| Q3 2022 | 120 | $692.3M |
| Q2 2022 | 105 | $870.9M |
| Q1 2022 | 99 | $1.15B |
| Q4 2021 | 105 | $1.10B |
| Q3 2021 | 92 | $1.31B |
| Q2 2021 | 86 | $1.44B |
| Q1 2021 | 81 | $1.31B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding PMV Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Boxer Capital, LLC | 2,838,236 | $65.6M | 2.61% | +570,000+25.1% | Added |
| RTW Investments, LP | 2,980,960 | $68.9M | 1.01% | +2,171,097+268.1% | Added |
| JPMorgan Chase & Co | 3,167,222 | $73.2M | 0.01% | +1,360,130+75.3% | Added |
| Interwest Venture Management Co | 3,234,911 | $74.7M | 44.17% | −635,000−16.4% | Reduced |
| OrbiMed Advisors LLC | 7,330,423 | $169.3M | 2.20% | 00.0% | Unchanged |
| Logos Global Management LP | 0 | $0 | 0.00% | −1,400,000−100.0% | Sold out |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −100,141−100.0% | Sold out |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −53,000−100.0% | Sold out |
| Driehaus Capital Management LLC | 0 | $0 | 0.00% | −35,000−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −27,199−100.0% | Sold out |
| TD Asset Management Inc | 0 | $0 | 0.00% | −17,600−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −12,716−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −8,610−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −29−100.0% | Sold out |
| Freed Investment Group | – | – | – | – | Not filed |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |